OKLO · Oklo Inc.

The thesis

Oklo Inc. has made real progress at its reactors and still has almost no revenue. Its shares keep falling while two share-sale programs of up to $1 billion each are open. The third-quarter report on 6 November 2026 decides whether a dated Aurora delivery schedule can outweigh the dilution. Oklo confirmed that date in a release on 23 October 2026.

The adjusted daily close was $26.35 on 23 October 2026. That is 81.6% below the $143.42 52-week high, and the shares fell 33.4% over three months. The 14-day relative strength index was 23.2. This index is a 0-100 momentum gauge, and readings under 30 are conventionally called oversold.

The narrative is saturated: nuclear power for artificial intelligence (AI) gets mainstream coverage, and four brokers cut their Oklo targets between 19 October 2026 and 22 October 2026. Barclays, Piper Sandler, Citigroup and Truist Securities made the cuts.

Bullish and bearish views on Oklo Inc.

The bull case on Oklo Inc. (OKLO), in brief: A reactor milestone is complete. The bear case: Share supply is open.

Bull case

• A reactor milestone is complete. Oklo reported first criticality at its Groves test reactor on 6 August 2026. The Department of Energy had authorized startup on 23 July 2026.
• Groves keeps producing news. Oklo announced a Groves isotope production milestone on 21 October 2026. On 13 October 2026 it said the Groves isotope facility would move forward under the Department of Energy's National Reactor Innovation Center Nuclear Energy Launch Pad initiative.
• A large customer agreement exists. Oklo and Meta announced an agreement on 9 January 2026 that supports a planned 1.2-gigawatt campus in southern Ohio. Oklo said the first phase could come online as early as 2030.
• Even reduced targets sit well above the price. Barclays kept its Overweight rating on 20 October 2026 while cutting its target to $59 from $76, as TIKR reported. Piper Sandler kept Overweight with a $49 target on 19 October 2026. TIKR, citing S&P Global data, put the consensus target near $75 in October 2026.

Bear case

• Share supply is open. Oklo filed a $1.0 billion at-the-market equity program on 13 May 2026. It filed a second equity-distribution agreement for up to $1 billion on 11 September 2026. Stock can be sold into any rally without a separate announcement.
• Revenue is negligible. On 7 August 2026 Oklo reported second-quarter 2026 revenue of $1.210 million. The loss was $0.28 per share, against a consensus loss of $0.16.
• Loss estimates are widening. TIKR reported in October 2026 that analysts expect a 2026 loss of $0.94 per share, compared with $0.73 ninety days earlier.
• Targets are falling fast. Truist cut its target from $51 on 10 August 2026 to $31 on 22 October 2026. Citigroup went from $57.50 to $33 on 21 October 2026, and Barclays from $146 in January to $59. The Truist and Citigroup targets now sit only a few dollars above the $26.35 close.
• Insiders sell on a schedule. The co-founders disclosed $13.6 million of share sales in Form 4 filings on 3 June 2026. Their Rule 10b5-1 plans are pre-arranged sale plans adopted on 31 March 2025, and they execute on the first business day of most months.

Price setup

The $26.35 close on 23 October 2026 is the lowest close in this dossier's coverage. It sits below the $27.01 close of 22 October 2026 and the $34.70 close of 9 October 2026. It is also under the $36.22 close of 11 September 2026, the day the second $1 billion agreement was filed.

The 14-day relative strength index of 23.2 shows heavy, one-way selling into the report. Crowding signals are on the supply side. Two issuance programs are open, scheduled founder sales are due in early November, and earnings land on 6 November 2026. A recovery above $34.70 would retake the close from before the latest round of target cuts.

Catalysts, next 30 days

• 2 November 2026. This is the first business day of November, when founder Rule 10b5-1 sales have executed in most months. Form 4 filings within two business days would show whether that supply continues.
• 6 November 2026, before the market opens. Oklo reports third-quarter 2026 results and holds a call at 8:30 a.m. Eastern, as its 23 October 2026 release confirmed. The report shows cash burn and any dated Aurora delivery schedule. The quarterly filing shows how much stock was sold under the two $1 billion programs.
• 9 November to 13 November 2026. Analyst target revisions typically follow the report. Further cuts toward the $26.35 close would extend the trend from 19 October to 22 October 2026.

What would change the view

The case breaks if the 6 November 2026 report gives no dated Aurora delivery schedule and shows heavy stock sales under the open programs. A daily close below $24.00 would also break it, because that would be a new low under the $26.35 close of 23 October 2026.

The reading would improve if the report puts a firm date on an Aurora regulatory or delivery milestone and shows limited use of the programs. A recovery above the $34.70 close of 9 October 2026 would also improve it. So would a stop to the target cuts after the report.

What it trades with

Benzinga reported on 25 August 2026 that Oklo rose along with uranium miners and advanced nuclear developers during US-Canada trade tensions. The shares move with that group. They also react to broader sell-offs in AI stocks and to long-term Treasury yields, which Benzinga reported near 20-month highs on 20 August 2026. With revenue of $1.210 million in the second quarter, company news and financing drive the shares more than earnings do.